Bionano Genomics, Inc. (BNGO) FinancialsBNGOBionano Genomics, Inc.

Bionano Genomics, Inc. (BNGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 58.3% of total sales, equivalent to $3.90M. Other significant revenue streams include Software and Instruments. Understanding this composition is critical for investors evaluating how BNGO navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Bionano Genomics, Inc. maintains a gross margin of 52.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -88.34%, while the net margin is -90.85%. These profitability ratios, combined with a Return on Equity (ROE) of -83.56%, provide a clear picture of how effectively BNGO converts its operational activities into shareholder value.

In the context of the broader market, BNGO competes directly with industry leaders such as INTS and RGNT. With a market capitalization of $13.90M, it holds a significant position in the sector. When comparing efficiency, BNGO's gross margin of 52.80% stands against INTS's N/A and RGNT's N/A. Such benchmarking helps identify whether Bionano Genomics, Inc. is trading at a premium or discount relative to its financial performance.

The total revenue for Q2 2026 was $8.17 million, showing a year-over-year increase, but the company continues to report net losses, with -7.42 million in Q2 2026 and a gross margin of 52.80%, indicating some operational improvements.